BCMA-directed CAR T-cell therapy may be effective against high-risk smoldering multiple myeloma
A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II ...
12 hours ago
0
1








